Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02955732
Other study ID # T280/2016
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 1, 2017
Est. completion date September 10, 2018

Study information

Verified date September 2018
Source Turku University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We aim to characterize the bioavailability and pharmacokinetics of dexmedetomidine after intranasal dosing employing pharmacometrics methods in otherwise healthy 1 month to 11 years of age children scheduled for minor surgery or other procedures requiring sedation or anesthesia.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 10, 2018
Est. primary completion date April 30, 2017
Accepts healthy volunteers No
Gender All
Age group 1 Month to 12 Years
Eligibility Inclusion Criteria:

- 1. The child is scheduled for intra-articular drug injections, hernia repair, bronchoscopy or another similar minor procedure or magnetic resonance imaging requiring sedation or anesthesia

- 2. Guardians and patient (if relevant) with fluent skills in the Finnish or Swedish language (to understand the given information, to be able to give informed consent and communicate with the study personnel).

- 3. Age between 1 month and 12 years.

- 4. Normal developmental status including growth (SD -1.5-1.5)

- 5. Written informed consent from the guardian and the patient (when relevant).

Exclusion Criteria:

- 1. A previous history of intolerance to the study drug or to related compounds and additives

- 2. Prior drug therapy with dexmedetomidine in the 14 days prior to the study.

- 3. Use of any drugs known to cause enzyme induction or inhibition for a period of 30 days prior to the study, use of any natural products (including grapefruit products) for at least 14 days prior to the study and caffeine containing products for at least 24 hours prior to the study. The use of regular doses of paracetamol is allowed.

- 4. Existing or recent significant disease that could influence the study outcome or cause a health hazard for the subject if he/she would participate in the study.

- 5. Participation in any other clinical study involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study.

- 6. Clinically significant abnormal findings in physical examination or laboratory screening [routine haematology (haemoglobin, haematocrit, red blood cell count, white blood cell count, platelets), renal function tests (creatinine, urea) and liver function tests (bilirubin)].

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Dexmedetomidine
A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasalâ„¢ -device approximately 20 min prior to planned sedation/anesthesia.

Locations

Country Name City State
Finland Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital Turku

Sponsors (2)

Lead Sponsor Collaborator
Turku University Hospital University of Turku

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relative bioavailability (%) of intranasally given dexmedetomidine 4 hours
Secondary Change in hemodynamic parameter (blood pressure) More than 30% change from the baseline in the blood pressure (measured in mmHg) 6 hours
Secondary Change in hemodynamic parameter (heart rate) More than 30% change from the baseline in the heart rate (measured in beats per minute) 6 hours
Secondary Number of patients with adverse events as a measure of safety and tolerability 6 hours
See also
  Status Clinical Trial Phase
Recruiting NCT03692390 - Virtual Reality vs. Standard-of-Care for Comfort Before and After Sedation in the Emergency Department N/A
Completed NCT02145169 - Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study N/A
Recruiting NCT05595798 - EEG Spectral Pattern of Deep Sedation-induced Airway Adverse Effects
Completed NCT01260662 - Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Phase 4
Completed NCT00784498 - Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department Phase 4
Completed NCT00327392 - A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. Phase 2/Phase 3
Recruiting NCT04873596 - Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia Phase 2
Completed NCT03329014 - A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability Phase 1
Recruiting NCT06414395 - The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study Phase 4
Recruiting NCT03860831 - Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities: Phase 1
Completed NCT00869440 - Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 2
Not yet recruiting NCT05757622 - Electroencephalogram Based Real-Time Sedation Level Prediction
Completed NCT03799783 - The Use of Dexmedetomidine for EEG Sedation in Children With Behavioural Disorders Phase 2
Completed NCT02180737 - Dexmedetomidine for Sedation During Radiological Interventional Procedures Phase 4
Not yet recruiting NCT01227174 - Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery Phase 4
Recruiting NCT03499886 - Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique Phase 2/Phase 3
Completed NCT03747432 - Comparison of Procedural Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Phase 4
Recruiting NCT06203522 - Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin
Withdrawn NCT05783492 - INK Feasibility Study Phase 3
Recruiting NCT04686448 - Ketofol Versus Fenofol as Procedural Sedation for Carpal Tunnel Release Phase 1/Phase 2